Company Filing History:
Years Active: 2003
Title: Michael A. Tigges: Innovator in Herpes Simplex Virus Vaccines
Introduction
Michael A. Tigges is a notable inventor based in Oakland, CA (US). He has made significant contributions to the field of immunology, particularly in the development of vaccines targeting the herpes simplex virus (HSV). His innovative work has the potential to impact the treatment and prevention of HSV infections.
Latest Patents
Michael A. Tigges holds 1 patent for his invention related to herpes simplex virus VP22 vaccines and methods of use. This patent discloses vaccines containing HSV VP22 polypeptides that are capable of eliciting a cellular immune response. The vaccines can also include additional HSV polypeptides, such as HSV glycoproteins. Furthermore, the patent outlines methods of DNA immunization, showcasing a comprehensive approach to combating HSV infections.
Career Highlights
Throughout his career, Michael has been associated with Chiron Corporation, a company known for its focus on biotechnology and pharmaceuticals. His work at Chiron has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in vaccine development.
Collaborations
Michael A. Tigges has worked alongside Rae Lyn Burke, a fellow innovator in the field. Their collaboration has likely fostered advancements in the research and development of effective vaccines.
Conclusion
Michael A. Tigges is a prominent figure in the field of vaccine innovation, particularly for herpes simplex virus. His contributions through patents and collaborations continue to pave the way for advancements in immunology and public health.